My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 415

    1.

    Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

    Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group.

    Diabetes Care. 2004 May;27(5):1081-7.PMID: 15111525 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin.

    Pieber TR, Draeger E, Kristensen A, Grill V.

    Diabet Med. 2005 Jul;22(7):850-7.PMID: 15975098 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.

    Clin Ther. 2004 May;26(5):724-36.PMID: 15220016 [PubMed - indexed for MEDLINE]Related articles

    4.

    Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

    Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA.

    Diabetologia. 2004 Apr;47(4):622-9.PMID: 15298338 [PubMed - indexed for MEDLINE]Related articles

    5.

    Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

    Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.

    Diabetes Care. 2003 Mar;26(3):590-6.PMID: 12610006 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.

    Standl E, Lang H, Roberts A.

    Diabetes Technol Ther. 2004 Oct;6(5):579-88.PMID: 15628811 [PubMed - indexed for MEDLINE]Related articles

    7.

    Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.

    Kølendorf K, Ross GP, Pavlic-Renar I, Perriello G, Philotheou A, Jendle J, Gall MA, Heller SR.

    Diabet Med. 2006 Jul;23(7):729-35.PMID: 16842476 [PubMed - indexed for MEDLINE]Related articles

    8.

    A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.

    Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P.

    Diabetes Care. 2006 Jun;29(6):1269-74. Erratum in: Diabetes Care. 2007 Apr;30(4):1035. PMID: 16732007 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.

    Clin Ther. 2008 Nov;30(11):1976-87.PMID: 19108786 [PubMed - indexed for MEDLINE]Related articles

    10.

    Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.

    Diabet Med. 2007 Jan;24(1):27-34.PMID: 17227321 [PubMed - indexed for MEDLINE]Related articles

    11.

    Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.

    Bartley PC, Bogoev M, Larsen J, Philotheou A.

    Diabet Med. 2008 Apr;25(4):442-9.PMID: 18387078 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.

    Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB.

    Diabetes Care. 2003 May;26(5):1490-6.PMID: 12716810 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.

    De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW.

    Diabetes Obes Metab. 2005 Jan;7(1):73-82.PMID: 15642078 [PubMed - indexed for MEDLINE]Related articles

    14.

    Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.

    Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB.

    Diabetes Care. 1999 Mar;22(3):468-77.PMID: 10097931 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.

    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.

    Diabetes Obes Metab. 2005 Jan;7(1):56-64.PMID: 15642076 [PubMed - indexed for MEDLINE]Related articles

    16.

    Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

    Yki-Järvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group.

    Diabetes Care. 2000 Aug;23(8):1130-6.PMID: 10937510 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

    Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M.

    Diabetes Care. 2001 Feb;24(2):296-301.PMID: 11213882 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.

    Davies MJ, Derezinski T, Pedersen CB, Clauson P.

    Diabetes Technol Ther. 2008 Aug;10(4):273-7.PMID: 18715200 [PubMed - indexed for MEDLINE]Related articles

    19.

    Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.

    Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B.

    Clin Ther. 2006 Oct;28(10):1569-81. Erratum in: Clin Ther. 2006 Nov;28(11):1967. PMID: 17157113 [PubMed - indexed for MEDLINE]Related articles

    20.

    Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

    Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N.

    Diabetes Res Clin Pract. 2004 Nov;66(2):193-201. Erratum in: Diabetes Res Clin Pract. 2006 Apr;72(1):112. PMID: 15533587 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity